Department of Emergency Medicine and Pre-Hospital Services, St. Olav's University Hospital, Prinsesse Kristinas Gate 3, 7006, Trondheim, Norway.
Department of Research and Development, Norwegian Air Ambulance Foundation, Oslo, Norway.
Scand J Trauma Resusc Emerg Med. 2023 Oct 31;31(1):69. doi: 10.1186/s13049-023-01142-5.
Resuscitative endovascular balloon occlusion of the aorta (REBOA) is increasingly used. The recently published UK-REBOA trial aimed to investigate patients suffering haemorrhagic shock and randomized to standard care alone or REBOA as adjunct to standard care and concludes that REBOA may increase the mortality.
In this commentary we try to balance the discussion on use of REBOA and address limitations in the UK-REBOA trial that may have influenced the outcome of the study.
The situation is complex, and the patients are in extremis. In summary, we do not think this is the end of balloons.
复苏性主动脉球囊阻断术（REBOA）的应用越来越多。最近发表的英国 REBOA 试验旨在调查出血性休克患者，并将其随机分为仅接受标准治疗或 REBOA 联合标准治疗，结果表明 REBOA 可能会增加死亡率。
在这篇评论中，我们试图平衡对 REBOA 使用的讨论，并解决 UK-REBOA 试验中的局限性，这些局限性可能影响了研究结果。
情况很复杂，患者处于危急状态。总之，我们不认为这就是气囊的终结。
